Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 24 September 2021
chronic myeloid leukemia
stem cell transplantation
graft versus host disease
myeloid leukemia
lymphoid leukemia
total body irradiation
hematologic malignancy
chronic lymphocytic leukemia
multiple myeloma
hodgkin's disease
white blood cell count
ejection fraction
cell transplantation
bone marrow procedure
lymphocytic leukemia
gilbert's syndrome
antithymocyte globulin
myeloproliferative syndromes
white blood cells
progressive disease
chemotherapy regimen
follicular lymphoma
mantle cell lymphoma
aplastic anemia
blood cell count
lymphocyte immune globulin


This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Cytokine-treated veto cells may help the transplanted donor cells to develop and grow in recipients without causing graft-versus-host-disease (GVHD - when transplanted donor tissue attacks the tissues of the recipient's body).



I. To determine the optimal dose of anti-viral veto cells, defined as the dose which achieves engraftment without severe graft-vs-host disease (GVHD) at 42 days after non-myeloablative megadose T cell depleted haploidentical hematopoietic cell transplantation (HCT).


I. Toxicity. II. Response rate. III. Time to progression. IV. Infections. V. Immune reconstitution. VI. Overall survival up to 1 year.

OUTLINE: This is a dose-escalation study of cytokine-treated veto cells.

CONDITIONING REGIMEN: Patients receive anti-thymocyte globulin (ATG) intravenously (IV) over 4 hours on days -9 to -7 and fludarabine IV over 1 hour on days -6 to -3, then undergo total body irradiation (TBI) on day -1.

TRANSPLANT: Patients undergo peripheral blood stem cell transplantation (PBSCT) IV over 30-60 minutes on day 0.

GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days +3 and +4 and cytokine-treated veto cells IV over 30-60 minutes on day +7.

After completion of stem cell transplant, patients are followed up once a week for 4 weeks, once a month for 3 months, and then periodically for one year.

Condition Bone marrow disorder, childhood ALL, Pancytopenia, Follicular Lymphoma, Hodgkin's Disease, organ donor, Multiple Myeloma, Lymphoma, Preleukemia, Anemia, Aplastic Anemia, Acute myeloid leukemia, Mantle cell lymphoma, Lymphoproliferative Disorder, Lymphoma, Chronic Lymphocytic Leukemia, MYELOPROLIFERATIVE DISORDER, MYELODYSPLASTIC SYNDROME, Chronic myeloid leukemia, Lymphocytic Leukemia, Chronic, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Myeloproliferative Neoplasms, Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Anemia; Non-Small-Cell Lung Cancer, Lymphocytic Leukemia, Acute, Anemia; Non-Hodgkin’s Lymphoma, Lymphoproliferative disorders, Hematopoietic Cell Transplant Recipient, Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia, acute lymphoblastic leukemia, leukemia, acute lymphoblastic, myelodysplastic syndromes, myeloproliferative neoplasm, myeloproliferative disorders, non-hodgkin's lymphoma (nhl), bone marrow failure, leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma, multiple myeloma (mm), myelodysplastic syndrome (mds), hodgkin, hodgkin's lymphomas, hodgkin lymphomas, hodgkins lymphoma, hodgkin's lymphoma, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia, anll, acute myeloblastic leukemia
Treatment anti-thymocyte globulin, cyclophosphamide, peripheral blood stem cell transplantation, Fludarabine, Total-Body Irradiation, Cytokine-treated Veto Cells
Clinical Study IdentifierNCT03622788
SponsorM.D. Anderson Cancer Center
Last Modified on24 September 2021

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note